Essential Facts About Biophytis SA

It hasn't been a great afternoon session for Biophytis SA investors, who have watched their shares sink by -4.57% to a price of $0.4. Some of you might be wondering if it's time to buy the dip. If you are considering this, make sure to check the company's fundamentals first to determine if the shares are fairly valued at today's prices.

Biophytis SA, a clinical-stage biotechnology company, focuses on the development of therapies that slow down degenerative processes and improve functional outcomes for patients suffering from age-related diseases and the treatment of severe respiratory failure in patients suffering from COVID- 19. The company belongs to the Basic Materials sector, which has an average price to earnings (P/E) ratio of 10.03 and an average price to book (P/B) ratio of 2.08. In contrast, Biophytis SA has a trailing 12 month P/E ratio of -0.18 and a P/B ratio of 1.353.

Biophytis SA has moved -87.27% over the last year compared to -9.23% for the S&P 500 — a difference of -78.04%. Biophytis SA has a 52 week high of $3.36 and a 52 week low of $0.35.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.